Table 1. Correlation between Pyk2, Pyk2[pY881] expression and clinicopathologic characteristics of NSCLC patients.
| Pyk2 expression: no. of patients (%) | Pyk2[pY881] expression: no. of patients (%) | |||||
|---|---|---|---|---|---|---|
|
Characteristics |
Lowa(58) |
Higha
(70) |
P-valueb |
Lowc
(51) |
Highc
(77) |
P-valueb |
|
Sex | ||||||
| Male | 38 (45.2) | 46 (54.8) | 0.981 | 30 (35.7) | 54 (64.3) | 0.187 |
| Female |
20 (45.5) |
24 (54.5) |
|
21 (47.7) |
23 (52.3) |
|
|
Age, years | ||||||
| ≦60 | 29 (42.6) | 39 (57.4) | 0.519 | 26 (38.2) | 42 (61.8) | 0.692 |
| >60 |
29 (48.3) |
31 (51.7) |
|
25 (41.7) |
35 (58.3) |
|
|
Smoking status | ||||||
| No | 29 (47.5) | 32 (52.5) | 0.629 | 28 (45.9) | 33 (54.1) | 0.182 |
| Yes |
29 (43.3) |
38 (56.7) |
|
23 (34.3) |
44 (65.7) |
|
|
CEAd | ||||||
| − | 30 (49.2) | 31 (50.8) | 0.381 | 28 (45.9) | 33 (54.1) | 0.102 |
| + |
20 (40.8) |
29 (59.2) |
|
15 (30.6) |
34 (69.4) |
|
|
NSEe | ||||||
| − | 27 (45.8) | 32 (54.2) | 0.376 | 25 (42.4) | 34 (57.6) | 0.361 |
| + |
10 (35.7) |
18 (64.3) |
|
9 (32.1) |
19 (67.9) |
|
|
EGFRf | ||||||
| − | 2 (14.3) | 12 (85.7) | 0.201 | 8 (57.1) | 6 (42.9) | 0.288 |
| + |
14 (37.8) |
23 (62.2) |
|
15 (40.5) |
22 (42.9) |
|
|
Histology | ||||||
| Adenocarcinoma | 43 (47.3) | 48 (52.7) | 0.489 | 33 (36.3) | 58 (63.7) | 0.194 |
| Squamous carcinoma |
15 (40.5) |
22 (59.5) |
|
18 (48.6) |
19 (51.4) |
|
|
Differentiation | ||||||
| Well–moderate | 31 (50.0) | 31 (50.0) | 0.302 | 33 (53.2) | 29 (46.8) | 0.003 |
| Poor |
27 (40.9) |
39 (59.1) |
|
18 (27.3) |
48 (72.7) |
|
|
T stageg | ||||||
| T1 | 17 (53.1) | 15 (46.9) | 0.236 | 19 (59.4) | 13 (40.6) | 0.033 |
| T2 | 34 (46.6) | 39 (53.4) | 24 (32.9) | 49 (67.1) | ||
| T3–T4 |
7 (30.4) |
16 (69.6) |
|
8 (34.8) |
15 (65.2) |
|
|
N stageg | ||||||
| N0 | 36 (55.4) | 29 (44.6) | 0.020 | 34 (52.3) | 31 (47.7) | 0.003 |
| N1–N3 |
22 (34.9) |
41 (65.1) |
|
17 (27.0) |
46 (73.0) |
|
|
M stageg | ||||||
| M0 | 55 (53.4) | 48 (46.6) | <0.001 | 47 (45.6) | 56 (54.7) | 0.007 |
| M1 |
3 (12.0) |
22 (88.0) |
|
4 (16.0) |
21 (84.0) |
|
|
Clinical stageg | ||||||
| I | 24 (61.5) | 15 (38.5) | 0.001 | 24 (61.5) | 15 (38.5) | 0.003 |
| II | 19 (55.9) | 15 (44.1) | 12 (35.3) | 22 (64.7) | ||
| III | 12 (40.0) | 18 (60.0) | 11 (36.7) | 19 (63.3) | ||
| IV | 3 (12.0) | 22 (88.0) | 4 (16.0) | 21 (84.0) | ||
Abbreviations: CEA=carcinoembryonic antigen; EGFR=epidermal growth factor receptor; NSCLC=non-small-cell lung cancer; NSE=neuron-specific enolase; Pyk2=proline-rich tyrosine kinase 2.
Pyk2 low expression: score ⩽3; high expression: score ⩾4.
Two-sided P-values were calculated by Pearson's χ2 test or continuity correction to evaluate the significance of correlations. Bold print indicates statistical significance.
Pyk2[pY881] low expression: score ⩽3; high expression: score ⩾4.
CEA: −, normal (0–5 ng ml−1); +, elevated (>5 ng ml−1); 18 patients' CEA unknown.
NSE: −, normal (0–15.2 ng ml−1); +, elevated (>15.2 ng ml−1); 41 patients' NSE unknown.
EGFR: −, no EGFR mutation and amplification; +, EGFR mutation or amplification; 77 patients' EGFR unknown.
Tumour size, lymph node involvement, distant metastasis and clinical stage were classified or reclassified according to the seventh edition of the International Union Against Cancer (UICC) Staging system for Lung Cancer.